Skip to content
Screener

Offering Costs at other companies

CEP
CEPTCEPT
$5.3M+19,713%
CEP
CEPTCEPT
$5.3M+19,713%
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
-$180K-169%
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
-$180K-169%
CEP
Cantor Equity Partners IV, Inc.CEPF
$8.6M
FCR
FutureCrest AcquisitionFCRS
$75K

Other financials

Income statement

See full
Revenue$19.1M+109%
Gross profit$4.5M+57.6%
Operating income-$2.5M-82.0%
Net income-$4.1M-14.6%
EPS (diluted)-$0.07-75.0%

Balance sheet

See full
Cash & equivalents$55.2M+753%
Total debt$11.4M-20.7%
Total equity$89.1M+467%
Total assets$144.3M+77.2%

Cash flow

See full
Operating cash flow-$6.8M-110%
CapEx$899.5K+114%
Free cash flow-$7.7M-110%

Valuation

See full
Market cap$820.03M+424%
Enterprise value$776.17M+379%
P/S13.1×+8.9×

Profitability

See full
Gross margin26.8%-1.7pp
Operating margin-29.5%+6.9pp
Net margin-37.4%+11.5pp
FCF margin-16.4%-2.1pp

Returns & leverage

See full
Return on equity-44.8%+2.1pp
Debt / equity0.1×-0.8×
Current ratio3.9×+1.6×

Where this comes from

Reported directly by Lightpath Technologies in its filing.

Tagged under the XBRL concept lpth:OfferingCosts.

The source filing: Lightpath Technologies’s 10-K, filed September 26, 2025.

Filed
Sep 26, 2025
Fiscal year
FY2025
Accession
0001654954-25-011130

In conjunction with the financing of the acquisition of G5 Infrared, the Company designated a new series of preferred stock, Series G Convertible Preferred Stock, which is convertible into shares of Class A Common Stock. Concurrent with the entry into the G5 MIPA on February 13, 2025, we entered into (i) a Securities Purchase Agreement (the “Securities Purchase Agreement”) by and among the Company and North Run Capital, AIGH Investment Partners, LP, WVP Emerging Manager Offshore Fund LLC, the Lytton-Kambara Foundation and Alice W. Lytton Family LLC (collectively, the “Series G Purchasers”), (ii) a Class A Common Securities Purchase Agreement (the “Class A SPA”) by and between the Company and Lytton-Kambara Foundation (the “Class A Purchaser”), and (iii) and two senior secured promissory notes in an aggregate principal amount of $5.2 million (the “Acquisition Notes”) for total proceeds of approximately $32.2 million, inclusive of the conversion of the bridge promissory note (the “Bridge Note”) (see Note 14, Loans Payable), and before deducting offering expenses of $2.2 million incurred by the Company, which was used to fund, in part, the cash consideration payable in connection with the acquisition of G5 Infrared. Pursuant to the Securities Purchase Agreement, the Series G Purchasers purchased from the Company (i) an aggregate of approximately 24,956 shares of Series G Convertible Preferred Stock, (ii) warrants to purchase an aggregate of 4,352,774 shares of Class A Common Stock, with an exercise price of $2.58 per share (the “Series G Purchasers Warrants”), and (iii) the Acquisition Notes, which are convertible into shares of Series G Convertible Preferred Stock limited to failure to achieve a certain EBITDA threshold (see Note 14, Loans Payable). The Securities Purchase Agreement closed on February 18, 2025.

Item 16. Form 10-K Summary.

FAQ

What is Lightpath Technologies's offering costs?
Lightpath Technologies (LPTH) reported offering costs of $550K in Q2 2025.
What does offering costs mean?
Direct costs incurred in connection with the issuance of equity or debt securities, such as underwriting fees, legal expenses, and registration costs. Monitoring these costs is important for understanding the efficiency of the company's capital-raising processes.

Ask your AI about Lightpath Technologies's offering costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude